Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future

Simple item page
dc.contributor.authorRao, M.
dc.contributor.authorIppolito, G.
dc.contributor.authorMfinanga, S.
dc.contributor.authorNtoumi, F.
dc.contributor.authorYeboah-Manu, D.
dc.contributor.authorVilaplana, C.
dc.contributor.authorZumla, A.
dc.contributor.authorMaeurer, M.
dc.date.accessioned2019-05-21T10:49:50Z
dc.date.available2019-05-21T10:49:50Z
dc.date.issued2019-03
dc.description.abstractMultidrug-resistant TB (MDR-TB) is a major threat to global health security. In 2017, only 50% of patients with MDR-TB who received WHO-recommended treatment were cured. Most MDR-TB patients who recover continue to suffer from functional disability due to long-term lung damage. Whilst new MDR-TB treatment regimens are becoming available, conventional drug therapies need to be complemented with host-directed therapies (HDTs) to reduce tissue damage and improve functional treatment outcomes. This viewpoint highlights recent data on biomarkers, immune cells, circulating effector molecules and genetics which could be utilised for developing personalised HDTs. Novel technologies currently used for cancer therapy which could facilitate in-depth understanding of host genetics and the microbiome in patients with MDR-TB are discussed. Against this background, personalised cell-based HDTs for adjunct MDR-TB treatment to improve clinical outcomes are proposed as a possibility for complementing standard therapy and other HDT agents. Insights into the molecular biology of the mechanisms of action of cellular HDTs may also aid to devise non-cell-based therapies targeting defined inflammatory pathway(s) in Mtb-driven immunopathology.en_US
dc.identifier.otherhttps://doi.org/10.1016/j.ijid.2019.01.039
dc.identifier.otherVolume 80, Supplement,Pages S62-S67
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/30133
dc.language.isoenen_US
dc.publisherInternational Journal of Infectious Diseasesen_US
dc.subjectMultidrug-resistant tuberculosisen_US
dc.subjectClinical studiesen_US
dc.subjectHost-directed therapiesen_US
dc.subjectPersonalised medicineen_US
dc.subjectImmunotherapyen_US
dc.subjectBiomarkersen_US
dc.titleImproving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the futureen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Improving treatment outcomes for MDR-TB — Novel host-directed therapies and personalised medicine of the future.pdf
Size:
1.48 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Bacteriology Department